» Articles » PMID: 34081757

The Benefits of Coronavirus Suppression: A Cost-benefit Analysis of the Response to the First Wave of COVID-19 in the United States

Overview
Journal PLoS One
Date 2021 Jun 3
PMID 34081757
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

This paper estimates the benefits and costs of state suppression policies to "bend the curve" during the initial outbreak of COVID-19 in the United States. We employ an approach that values benefits and costs in terms of additions or subtractions to total production. Relative to a baseline in which only the infected and at-risk populations mitigate the spread of coronavirus, we estimate that total benefits of suppression policies to economic output are between $632.5 billion and $765.0 billion from early March 2020 to August 1, 2020. Relative to private mitigation, output lost due to suppression policies is estimated to be between $214.2 billion and $331.5 billion. The cost estimate is based on the duration of nonessential business closures and stay-at-home orders, which were enforced between 42 and 65 days. Our results indicate that the net benefits of suppression policies to slow the spread of COVID-19 are positive and may be substantial. We discuss uncertainty surrounding several parameters and employ alternative methods for valuing mortality benefits, which also suggest that suppression measures had positive net benefits.

Citing Articles

Understanding public perceptions in social media responses to posts about acute severe hepatitis of unknown etiology in Indonesia: a qualitative study.

Asa G, Fauk N, Gesesew H, Foley K, Lunnay B, Ward P BMC Infect Dis. 2023; 23(1):306.

PMID: 37158814 PMC: 10165573. DOI: 10.1186/s12879-023-08195-y.


Economic evaluation of strategies against coronavirus: a systematic review.

Izadi R, Hatam N, Baberi F, Yousefzadeh S, Jafari A Health Econ Rev. 2023; 13(1):18.

PMID: 36933043 PMC: 10024293. DOI: 10.1186/s13561-023-00430-1.


The German COVID-19 Digital Contact Tracing App: A Socioeconomic Evaluation.

Ellmann S, Maryschok M, Schoffski O, Emmert M Int J Environ Res Public Health. 2022; 19(21).

PMID: 36361198 PMC: 9654962. DOI: 10.3390/ijerph192114318.


What scientists have learnt from COVID lockdowns.

Lewis D Nature. 2022; 609(7926):236-239.

PMID: 36071184 DOI: 10.1038/d41586-022-02823-4.


Cost-effectiveness of interventions for the prevention and control of COVID-19: Systematic review of 85 modelling studies.

Zhou L, Yan W, Li S, Yang H, Zhang X, Lu W J Glob Health. 2022; 12:05022.

PMID: 35712857 PMC: 9196831. DOI: 10.7189/jogh.12.05022.


References
1.
Neumann P, Cohen J, Weinstein M . Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014; 371(9):796-7. DOI: 10.1056/NEJMp1405158. View

2.
Horwitz L, Jones S, Cerfolio R, Francois F, Greco J, Rudy B . Trends in COVID-19 Risk-Adjusted Mortality Rates. J Hosp Med. 2020; 16(2):90-92. DOI: 10.12788/jhm.3552. View

3.
Dasta J, McLaughlin T, Mody S, Piech C . Daily cost of an intensive care unit day: the contribution of mechanical ventilation. Crit Care Med. 2005; 33(6):1266-71. DOI: 10.1097/01.ccm.0000164543.14619.00. View

4.
Bright C, Burton C, Kosky M . Considerations of the impacts of COVID-19 on domestic violence in the United States. Soc Sci Humanit Open. 2021; 2(1):100069. PMC: 7539928. DOI: 10.1016/j.ssaho.2020.100069. View

5.
Russell T, Hellewell J, Jarvis C, van Zandvoort K, Abbott S, Ratnayake R . Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020. Euro Surveill. 2020; 25(12). PMC: 7118348. DOI: 10.2807/1560-7917.ES.2020.25.12.2000256. View